Expertise in
16
conditions

Dr. Claire F. Verschraegen

Oncology
Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, 
Columbus, OH 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, 
Columbus, OH 

Overview

Claire Verschraegen is an Oncologist practicing medicine in Columbus, Ohio.

Dr. Verschraegen is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Merkel Cell Carcinoma, Melanoma, and Head and Neck Squamous Cell Carcinoma (HNSCC).

She is actively involved in clinical research, co-authoring 98 peer reviewed articles and participating in 15 clinical trials. Dr. Verschraegen is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in VT

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, Columbus, OH 43221

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients With Advanced Cutaneous Malignancies (ARTACUS)
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2026
Intervention Type: Biological
Study Drug: RP1 Genetically-Modified Herpes Simplex Type 1 Virus
Study Phase: Phase 1/Phase 2
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
View 9 Less Clinical Trials

98 Total Publications

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.
Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.
Journal: Research square
Published: September 03, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Osu Medical Center

320 W 10th Ave, 
Columbus, OH 
 (1.0 miles away)
614-293-8629
Languages Spoken:
English
See accepted insurances

Manisha Shah is an Oncologist practicing medicine in Columbus, Ohio. Dr. Shah is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Thyroid Cancer, Medullary Thyroid Carcinoma, Pancreaticoduodenectomy, and Liver Embolization.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
 (1.0 miles away)
614-366-7744
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Carbone is an Oncologist practicing medicine in Columbus, Ohio. Dr. Carbone is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Carbone is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (0.9 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alice Mims is an Oncologist practicing medicine in Columbus, Ohio. Dr. Mims is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Mims is currently accepting new patients.

Frequently Asked Questions about Dr. Claire F. Verschraegen

How do I make an appointment with Dr. Claire F. Verschraegen?

You can book an appointment with Dr. Claire F. Verschraegen by calling their office at 614-293-3890. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Claire F. Verschraegen a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Claire F. Verschraegen is classified as an Distinguished expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Claire F. Verschraegen specialize in?

While Dr. Claire F. Verschraegen is a Oncology, they have specific expertise in Neuroendocrine Tumor, Merkel Cell Carcinoma, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Claire F. Verschraegen participate in research or clinical trials?

Yes. Dr. Claire F. Verschraegen has published 98 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Claire F. Verschraegen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Claire F. Verschraegen accept my insurance?

Dr. Claire F. Verschraegen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-3890 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Verschraegen's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile